Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index; 3 of the 11 sources its claims cite were checked for support.

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

Open access
Zeng, Qingyue, Xu, Jiao, Mu, Xingyu, Shi, Yi, Fan, Hong, Li, Shuangqing · 2023 · Frontiers in Endocrinology

Abstract

Purpose: A systematic review and meta-analysis was conducted to synthesize the available data from clinical trials and assess the safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes (T2D) and obesity. Methods: A systematic search was conducted in three electronic databases, namely Embase, PubMed, and the Cochrane Library, up until March 1, 2023, to identify randomized controlled trials (RCTs) comparing tirzepatide to either placebo or active hypoglycemic drugs in individuals with T2D and obesity. Heterogeneity was assessed using the I2 value and Cochran's Q test, and a fixed effects model was employed to estimate the safety profile of tirzepatide. The safety outcomes of interest, including pancreatitis, the composite of gallbladder or biliary diseases, cholecystitis, and cholelithiasis and biliary diseases, were evaluated. (The composite of gallbladder or biliary diseases incorporated cholelithiasis, cholecystitis, other gallbladder disorders, and biliary diseases.). Results: A total of nine trials with 9871 participants (6828 in the tirzepatide group and 3043 in the control group) that met the pre-specified criteria were included. When compared to all control groups consisting of basal insulin (glargine or degludec), selective GLP1-RA (dulaglutide or semaglutide once weekly), and placebo, an increased risk of pancreatitis was not found to be significantly associated with tirzepatide (RR 1.46, [95% CI] 0.59 to 3.61; I2 = 0.0%, p = 0.436). For gallbladder or biliary disease, the composite of gallbladder or biliary disease was significantly associated with tirzepatide compared with placebo or basal insulin (RR 1.97, [95% CI] 1.14 to 3.42; I2 = 0.0%, p = 0.558), but not with the risk of cholelithiasis, cholecystitis or biliary diseases. Conclusion: Based on the currently available data, tirzepatide appears to be safe regarding the risk of pancreatitis. However, the increased risk of the composite outcome of gallbladder or biliary diseases observed in RCTs warrants further attention from physicians in clinical practice. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023412400.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of nine RCTs found tirzepatide was not significantly associated with increased pancreatitis risk, but it was associated with an increased composite risk of gallbladder or biliary diseases versus placebo or basal insulin. The authors conclude tirzepatide appears safe regarding pancreatitis, while the gallbladder/biliary signal warrants clinical attention.

Key findings

  • Across nine trials with 9,871 participants (6,828 tirzepatide; 3,043 control), tirzepatide was not significantly associated with pancreatitis versus all controls: RR 1.46, 95% CI 0.59–3.61; I² = 0.0%, p = 0.436.
  • The composite of gallbladder or biliary diseases was significantly associated with tirzepatide compared with placebo or basal insulin: RR 1.97, 95% CI 1.14–3.42; I² = 0.0%, p = 0.558.
  • No significant association was found for cholelithiasis, cholecystitis, or biliary diseases individually, or for the composite when compared with GLP1-RA.
  • In dosage subgroup analysis, 10 mg tirzepatide was associated with increased composite gallbladder or biliary disease risk versus all controls: RR 1.91, 95% CI 1.14–3.19; I² = 0.0%, p = 0.880; no significant association was observed for 5 mg or 15 mg.

Methods

  • Systematic search of Embase, PubMed, and Cochrane Library up to March 1, 2023, for RCTs of at least 24 weeks comparing tirzepatide with placebo or active hypoglycemic drugs in T2D and obesity.
  • Nine RCTs included; outcomes were pancreatitis, composite gallbladder or biliary diseases, cholecystitis, cholelithiasis, and biliary diseases.
  • Fixed-effects meta-analysis using Stata 17; heterogeneity assessed with I² and Cochran’s Q; sensitivity and subgroup analyses by dose and control measure; publication bias assessed with Begg’s and Egger’s tests.

Limitations

  • The paper states included studies were not specifically designed to evaluate tirzepatide safety for pancreatitis and gallbladder/biliary disease, which may have led to incomplete outcome ascertainment.
  • The paper states some gallbladder or biliary diseases were not pre-specified safety outcomes in included studies, leading to potential under-reporting; population characteristics were somewhat heterogeneous.
  • The paper also lists general meta-analysis limitations: bias/confounding, variability in data quality, publication bias, and heterogeneity. Evident from the text: only nine trials were included, funnel plots were not drawn because fewer than 10 studies were available, and three studies did not blind participants and personnel.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fendo.2023.1214334

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flow diagram of the study.
Figure 1 Flow diagram of the study.CC BY · PubMed Central
Figure 2 Risk Ratio in pancreatitis: tirzepatide vs control groups.
Figure 2 Risk Ratio in pancreatitis: tirzepatide vs control groups.CC BY · PubMed Central
Figure 3 Flowchart of subgroup analysis.
Figure 3 Flowchart of subgroup analysis.CC BY · PubMed Central

Verification

Claims the paper makes

3 Valid · 0 Not valid · 4 Not checked · 29 Own results and interpretations

11 more claims

Create a free account to see all 36 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 15
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 44 references

Cited by

See all 67

Metadata

Authors
Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S.
Affiliations
Sichuan University (CN)
Corresponding author
  • Fan, Hong
  • Li, Shuangqing
Venue
Frontiers in Endocrinology
Published
2023-10-16
Volume
14
Pages
1214334-1214334
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4387670410
Cited by
66
References
44
Citations by year
2026: 18 · 2025: 34 · 2024: 14
FWCI
2.37
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, pancreatitis, gallbladder disease, biliary tract diseases, gallstones, cholecystitis, type 2 diabetes, obesity, drug safety, GLP-1 receptor agonists, basal insulin, dulaglutide, semaglutide, adverse events, drug-drug interactions, drug-disease interactions, pharmacovigilance
MeSH terms
Insulin Glargine, Tirzepatide, Cholecystitis, Cholelithiasis, Diabetes Mellitus, Type 2, Humans, Obesity, Pancreatitis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fendo.2023.1214334
The paper
Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1214334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.